2023 ANNUAL REPORT
The 2023 annual report outlines Alpha-1 Org Australia’s commitment to supporting for individuals suffering with Alpha-1.
2022 ANNUAL REPORT
The 2022 annual report outlines Alpha-1 Org Australia’s commitment to supporting for individuals suffering with Alpha-1.
2021 ANNUAL REPORT
The 2021 annual report outlines Alpha-1 Org Australia’s commitment to supporting for individuals suffering with Alpha-1.
FACT SHEET: PANNICULITIS
Panniculitis is a very rare but treatable condition, sometimes related to A1AD. Its estimated prevalence is one in 1,000 patients with the Pi*ZZ A1AD genotype.
BROCHURE: A1AD OVERVIEW
A1AD is a common genetic (inherited) disorder associated with low levels of a natural protein known as Alpha-1 Antitrypsin (AAT). Low levels of AAT can cause a number of diseases.
BROCHURE: A1AD HEALTH ISSUES
A1AD is a complicated and sometimes challenging diagnosis. Not everyone with abnormal Alpha-1 Antitrypsin Deficiency (AAT) is affected by the deficiency.
BROCHURE: QUESTIONS for YOUR Dr.
You are likely to have a lot of questions following a diagnosis of Alpha-1 Antitrypsin Deficiency (A1AD). Select the questions in the attachment that best relate to you.
FACT SHEET: AUGMENTATION THERAPY
There is only one treatment available to protect the lungs of people with A1AD. The treatment is Alpha-1 proteinase inhibitor (also called Augmentation Therapy).
POSITION PAPER: GAYNOR HEADING Phd
A position paper from Gaynor Heading PhD (Med), President of Alpha-1 Organisation Australia, focusing on preventing harm and saving lives for individuals with A1AD.